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Summary An in vitro model of acquired melphalan resistance was developed by serial incubation of an
MCF-7 human breast cancer cell line in increasing concentrations of melphalan. The resulting derivative cell
line, Mel R MCF-7, was 30-fold resistant to melphalan. Uptake studies demonstrated decreased initial
melphalan accumulation in MelR MCF-7 cells. Inverse-reciprocal plots of initial melphalan uptake revealed a
4-fold decrease in the apparent Vmax of MelR MCF-7 compared with WT MCF-7 (516 amol cell-' min-' vs
2110 amol cell-' min-' respectively) as well as a decrease in the apparent Kt (36 JAM vs 70 JAM respectively).
Two amino acid transporters have previously been identified as melphalan transporters: system L, which is
sodium-independent and inhibited by 2-amino-bicyclo[2,2,l]heptane-2-carboxylic acid (BCH), and system ASC
which is sodium dependent and unaffected by BCH. At low concentrations of melphalan (3-30 M), ImM
BCH competition eliminated the differences between the two cell lines, thus implicating an alteration of the
system L transporter in the transport defect in the resistant cells. MelR MCF-7 cells were also evaluated for
glutathione-mediated detoxification mechanisms associated with melphalan resistance. There was no difference
between MelR MCF-7 and WT MCF-7 in glutathione content, glutathione-S-transferase activity and expres-
sion of pi class glutathione S-transferase RNA. In addition, buthionine sulfoximine did not reverse melphalan
resistance in MelR MCF-7 cells. Therefore, MelR MCF-7 cells provide an in vitro model of transport-
mediated melphalan resistance in human breast cancer cells.
Alkylating agent therapy is central to the chemotherapeutic
approach to most malignancies, yet relatively few mech-
anisms of alkylating agent resistance have been described. In
particular, while transport-mediated resistance has been well-
characterised for many antineoplastic agents, most notably
the multidrug resistance phenotype associated with the drug
efflux pump P-glycoprotein, little is known about mech-
anisms of uptake, accumulation and efflux of alkylating
agents. Cellular resistance to alkylating agents has generally
been attributed to mechanisms which either detoxify the
agent or repair its damage.
Melphalan (1-phenylalanine mustard, L-PAM, Alkeran) is
a rationally designed alkylating agent which incorporates the
amino acid phenylalanine as a part of its structure. Mel-
phalan is active against ovarian cancer, myeloma, breast
cancer and rhabdomyosarcoma. Most in vitro models of
melphalan resistance have involved glutathione-mediated
pathways, a finding observed in a wide variety of rodent cell
lines including Chinese hamster ovary (Begleiter et al., 1983)
and murine L1210 leukaemia cells (Ahmad et al., 1987a;
Ahmad et al., 1987b); and human cell lines, including ovarian
(Green et al., 1984), myeloma (Gupta et al., 1989; Bellamy et
al., 1991) and prostate (Bailey et al., 1992) cells.
In this report we characterise a melphalan resistant MCF-7
human breast cancer cell line (MelR MCF-7) which was
isolated by serial incubation of the parental cell line in
increasing concentrations of melphalan. This model of mel-
phalan resistance differs from other human in vitro models of
melphalan resistance in that the MelR MCF-7 cells have a
significant defect in melphalan uptake associated with their
resistance. In addition, unlike most other melphalan resistant
cell lines reported, MelR MCF-7 cells have not developed
changes in glutathione and glutathione-dependent pathways.
Materials and methods
Cell and culture conditions
WT MCF-7 and MelR MCF-7 cells were grown in Improved
Minimal Essential Medium (IMEM) with (Gibco) and 5%
(vol/vol) foetal calf serum (Gibco) as previously described
(Batist et al., 1986). Cells were maintained at 37°C in a 5%
C02-95% air atmosphere.
Correspondence: J.A. Moscow, Building 10, Room 12N226,
National Institutes of Health, Bethesda, MD 20892, USA.
Received 20 March 1993; and in revised form 9 June 1993.
Drugs
Melphalan was obtained either from Burroughs Wellcome
(Research Triangle Park, NC) or from Sigma, and was
freshly prepared by dissolving aliquots in acidified ethanol at
a concentration of 10 mg per 100 IL ethanol. BSO was
obtained from the Drug Development Branch, NCI and
Sigma.
Selection ofmelphalan-resistant MCF-7 cells
MelR MCF-7 cells were isolated by serial incubation of WT
MCF-7 cells in increasing concentrations of melphalan over a
14 month period. WT MCF-7 cells were plated and exposed
to drug simultaneously. When surviving cells reached
confluence, the cells were split and exposed to gradually
increasing concentrations of drug. The starting melphalan
concentration was 0.05 .tM. At concentrations of 2JLM and
6tLM melphalan, the cells required repeated rescue with drug-
free medium after plating the cells in drug. After several
months a subpopulation emerged that could grow to
confluence from a low cell density in medium containing
6 ZtM melphalan. The cells were then passaged in medium in
which the melphalan concentration was gradually increased
to 40gM. MelR MCF-7 cells could not survive passages at
concentrations greater than 60lIM despite several attempts.
MelR MCF-7 cells were grown in drug-free medium for at
least 1 week and as long as 2 months prior to cytotoxicity
and drug accumulation studies.
Cytotoxicity andgrowth assays
A semi-automated sulforhodamine dye-based microtiter-plate
assay was used for cytotoxicity and growth assays. WT
MCF-7 (3,000 cells/well) and MelR MCF-7 (6,000 cells/well)
were plated into 96-well microtiter plates in 100,l of IMEM
with 5% foetal calf serum. On the following day, serial
dilutions of melphalan were added in another 100ftI medium.
The duration of exposure to melphalan was limited by the
relatively brief half-life of the drug; in infusion fluids, the t1/2
of melphalan at 37°C is approximately 3 h (Tabibi &
Cradock, 1984). On the fifth day, the cells were fixed with
50yl of 50% tricarboxylic acid for 1 h at 4'C, washed with
water and allowed to air dry, stained with 0.4% sulfo-
rhodamine in 1% acetic acid for 10min, washed five times
with 1% acetic acid and allowed to dry (Skehan et al., 1990).
The stained cells were solubilised in 10 mm Tris base
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pH 10.5, and the absorbance at 540 nm was determined on a
microplate reader (Skehan et al., 1990). The survival fraction
at a particular drug concentration was calculated as the per-
cent of mean absorbance values relative to the mean absor-
bance values of cells grown in the absence of drug. The IC%
value was calculated from the dose response curves as the
concentration ofdrug which would produce a 50% decrease in
the mean absorbance compared to the untreated wells. The
relative resistance of MelR MCF-7 cells was expressed as the
ratio of MelR MCF-7 IC50 values to WT MCF-7 IC50
values. All cytotoxicity assays were performed at least three
separate times in triplicate. Cytotoxicity assays involving
BSO were performed by adding 100tLM BSO to cells 4 h after
plating and 24h prior to the addition of melphalan. This
exposure to BSO is comparable to that reported to
significantly decrease glutathione levels in multidrug resistant
MCF-7 cells (Kramer et al., 1988; Dusre et al., 1989).
Growth assays were also performed with the sulfo-
rhodamine technique. Cells were plated in medium in 96 well
microtiter plates, and stained and fixed every 24 h. Doubling
times were derived from the slopes of the linear part of each
of the growth curves.
Transport studies
Melphalan uptake studies were performed as follows: WT
MCF-7 and MelR MCF-7 cells were plated in either 6- or
12-well Linbro dishes. Approximately 48 h after plating, dur-
ing the exponential growth phase, the cells were washed three
times with PAG transport medium (Dulbecco's phosphate
buffered saline containing 6.8 g 1` albumin and 1 g 1'- glu-
cose) pre-warmed to 37°C. Transport medium containing
[14C] melphalan (Moravek) was then added to the cells and
incubated at 37°C for the specified time. At the end of the
uptake period, the medium was quickly aspirated, and the
plates were immersed in four consecutive baths of ice-cold
Dulbecco's phosphate buffered saline in rapid succession.
The plates were blotted dry, and the cells were solubilised by
overnight incubation in 0.2 N NaOH at room temperature.
The cell lysates were neutralised with 0.2 N HCI and the
radioactivity determined by liquid scintillation counting.
Amino acids used for transport inhibition studies were
obtained from Gibco and BCH was obtained from Cal-
biochem. Competitors were added to the transport medium
containing radiolabelled melphalan, so that cells were simul-
taneously exposed to radiolabelled melphalan and excess
unlabelled competitor. Melphalan uptake at 0°C was minimal
(less than 5% of the uptake at 37°C; Figure 2). The uptake at
0°C was determined and subtracted from the uptake
measured at 37°C for each Lineweaver-Burke plot data point.
For uptake studies, the total number of cells was deter-
mined in replicate plates. Cells were trypsinised, resuspended
in medium, passed several times through a 19 gauge needle to
make a single cell suspension, diluted in isotonic buffered
saline, and counted in a Coulter counter.
Protein studies
Cytosolic glutathione S-transferase activity was determined
by using 1-chloro-2,4 dinitrobenzene as substrate (Habig &
Jakoby, 1981). One unit of glutathione S-transferase enzyme
activity is defined as the amount catalysing the conjugation
of the substrate with glutathione at the rate of 1 nmol min-'.
Total glutathione levels were determined on cell cytosol by
the cyclic reduction of oxidised glutathione with glutathione
reductase and NADPH as described by Tietze (1969).
Cytosolic protein was extracted from washed cells by son-
ication and centrifugation of the cell pellet, and the protein
concentration of the cytosols was determined spectrophoto-
metrically using Coomassie Plus protein assay reagent
(Pierce).
Nucleic acid studies
For Northern analysis, RNA was isolated by guanidine
isothiocyanate-cesium chloride gradient centrifugation (Sam-
brook et al., 1989) and the concentration was determined by
spectrophotometry. The RNA samples (10 pg) were size
fractionated on a 1% agarose gel that contained 2% for-
maldehyde using a buffer consisting of 20 mM MOPS con-
taining 1 mM EDTA and 5 mM sodium acetate. Equivalence
of RNA loading of the samples was confirmed by ethidium
bromide staining of the gel. The RNA was transferred onto a
Nytran membrane (Schleicher & Schuell), baked 2 h in an
80°C vacuum oven and hydridised overnight with a [32p]_
labelled cDNA probe for GSTP-1 (GSTn-1; Moscow et al.,
1988). The blot was washed with a final stringency of
0.1 x SSC and 0.1% SDS at 65°C and hybridisation was
detected by autoradiography.
Results
Selection ofmelphalan resistant MCF-7 cells
Melphalan resistant MCF-7 cells were developed by serial
incubation of MCF-7 cells in increasing concentrations of
melphalan as described in Methods. The melphalan dose-
response curve of the resulting subline, MelR MCF-7, is
shown in Figure 1. The melphalan IC,0 of MelR MCF-7
cells is 52 ZlM, compared to 1.7 J.M for WT MCF-7 cells.
Thus, MelR MCF-7 cells are 30-fold resistant to melphalan
at the IC50 level.
MelR MCF-7 cells have a lower plating efficiency than
WT MCF-7 cells, 31 ± 1% and 51 ± 7% respectively. In
addition, MeIR MCF-7 cells grow slower than WT MCF-7
cells, with a doubling time of 47 ± 3 h vs 27 ± 1 h for MelR
MCF-7 and WT MCF-7 cells respectively. MeIR MCF-7
cells contain slightly more cytosolic protein per cell than the
parental cell line (101 ± 7 vs 80 ± 1 jg 10-6 cells).
Resistance to melphalan in MelR MCF-7 cells gradually
declined when the cells were maintained in the absence of
drug. After 2 months passage in the absence of drug, resis-
tance to melphalan decreased to an IC50 of 40 ZtM and further
decreased to an IC50 of 20 fLM after 4 months passage without
exposure to the selecting agent. Therefore, after 4 months
passage out of drug, MelR MCF-7 cells retained 12-fold
level of resistance to melphalan in comparison to WT MCF-7
cells. The gradual loss of resistance seen in MelR MCF-7
cells when passaged out of drug suggests that resistance may
be the result of gene amplification. Cytogenetic analysis of
MelR MCF-7 cells has revealed minute chromosomes in 17
of 30 metaphases examined (W. Peterson, personal com-
munication).
Melphalan transport studies
The cellular uptake of 50 SM melphalan over a 30 min time
course is shown in Figure 2. This plot demonstrates a 4-fold
decrease in melphalan accumulation in MelR MCF-7 cells in
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Figure 1 Cytotoxicity assay of melphalan on WT MCF-7 and
MelR MCF-7 cells. Cell growth after continuous exposure to
melphalan was determined relative to untreated controls using a
sulforhodamine dye assay as described in the Methods section.
The graph indicates the mean ± s.d. of six separate determina-
tions performed in triplicate.734 J.A. MOSCOW et al.
comparison to WT MCF-7 cells. The uptake appears to be
linear over the first 6min, and then reaches a plateau by
20 min. The time over which linear uptake occurs is longer
than that observed in L1210 cells (Redwood & Colvin, 1980),
but comparable to that previously observed in MCF-7 cells
(Begleiter et al., 1980). Melphalan uptake at 4°C was minimal
(Figure 2).
An inverse-reciprocal plot of melphalan uptake at 2 min
over a concentration range of 1-300IM is shown in Figure
3. The Kt and Vmax for melphalan for each cell line was
determined by linear regression analysis. For WT MCF-7
cells, the apparent Kt was 70 1LM and the Vmax was
2110amolcell-1min-'. For MeIR MCF-7 cells, the Kt was
36f1M and the Vmax was 516amolcell-1min-'. Therefore,
while there may be some qualitative changes in the apparent
Kt, the major difference between MelR MCF-7 and WT
MCF-7 cell lines appears to be related to the 4-fold decrease
in the Vmax.
Previous studies of melphalan uptake have attributed mel-
phalan uptake to two amino acid transport systems
(Goldenberg et al., 1979; reviewed by Vistica, 1983). One
transporter is similar to the amino acid transport System L
which preferentially transports leucine, but also transports
phenylalanine, tyrosine, tryptophan and valine. System L is
inhibited by the synthetic inert amino acid BCH and is
sodium independent. The other transporter is similar, if not
identical, to System ASC (for alanine, serine, cysteine) which
is sodium dependent and unaffected by BCH.
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In order to determine which amino acid transport system
was responsible for melphalan uptake in WT MCF-7 and
Mel R MCF-7 cells, we examined initial uptake in the
absence of sodium and in the presence of BCH. Initial mel-
phalan (100 JIM) uptake when choline was substituted for
sodium in the transport medium was 102 ± 1% in WT MCF-
7 cells, and 81 ± 9% in MelR MCF-7 cells relative to uptake
of drug measured in PAG transport medium. Thus, a
sodium-independent mechanism accounts for most, if not all,
of the melphalan transport in both WT MCF-7 and MelR
MCF-7 cells.
The effect of BCH inhibition of melphalan uptake is
shown in Figure 4. As can be seen by the inverse reciprocal
plots, 1 mM BCH eliminates the difference between MelR
MCF-7 and WT MCF-7 cells in the initial melphalan uptake
over the concentration range of 3 to 30JiM. This finding
suggests that the difference in melphalan uptake between the
two cell lines can be ascribed to an alteration in the System L
transporter. BCH competition studies, seen in both Figures 4
and 5, also demonstrate that non-System L-mediated trans-
port is a small but significant mechanism of melphalan
uptake in both cell lines.
Melphalan uptake competition studies in the presence of
excess unlabelled amino acids (Figure 5) supports the impor-
tance of the System L transporter in the two cell lines.
System L substrates, such as leucine, phenylalanine, tyrosine
and tryptophan, were more effective in inhibiting initial mel-
phalan uptake than the amino acids which are poor sub-
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Figure 2 Melphalan accumulation in WT MCF-7 and MelR
MCF-7 cells. Uptake of 50 M melphalan was determined from
0.5 to 30 min in PAG transport medium at 37°C and 4°C as
described in the Methods section. The graph indicates the
mean ± s.d. of two separate determinations performed in dup-
licate.
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Figure 3 An inverse-reciprocal plot of melphalan uptake
between 1- 300JIM in WT MCF-7 and MelR MCF-7 cells. Initial
melphalan uptake was measured at 2 min at 37°C as described in
the Methods section. The linear regression solutions are for WCT
MCF-7 y = 4.714e-4 + 3.3187e-2x with a regression coefficient of
0.999; and for MelR MCF-7 y = 1.9386e-3 + 70449e-2x with a
regression coefficient of 0.999. The graph indicates the mean +
s.d. of four separate determinations performed in triplicate.
Figure 4 An inverse reciprocal plot of initial 2 min uptake of 3
to 30 JM melphalan in MeIR MCF-7 and WT MCF-7 cells in the
presence and in the absence of 1 mM BCH. The linear regression
solutions are: WT MCF-7, y = 1.5943e-4 + 3.6310e-2x with a
regression coefficient of 0.996; WT MCF-7 in 1 mM BCH,
y = 4.4915e-3 + 0.1556x with a regression coefficient of 0.990;
MeIR MCF-7, y = 1.4266e + 7.857e-2x with a regression
coefficient of 1.000; and MeIR MCF-7 in 1 mm BCH,
y = 3.6165e 3 + 0.1511x with a regression coefficient of 0.994.
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Figure 5 Bar graph representation of inhibition of initial 2 min
uptake of 100JIM melphalan by 300JIM of various competitors at
37'C. MEI, melphalan; cys, cystine; ser, serine; arg, arginine; glu,
glutamine; his, histidine; val, valine; try, tryptophan; tyr, tyrosine;
leu, leucine; val, valine. The graph indicates the mean ± s.d. of at
least three separate determinations performed in duplicate or
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strates for System L, such as arginine, cystine and serine
(Christensen, 1990).
Melphalan efflux was examined in both cell lines after
incubation in radiolabelled melphalan. As shown in Figure 6,
there was no difference in melphalan efflux between the two
cell lines after the initial loading period. Therefore, drug
efflux does not appear to contribute to the decreased mel-
phalan accumulation seen in MelR MCF-7 cells.
Glutathione-dependent detoxification
We examined MelR MCF-7 cells for alterations in glut-
athione and its dependent enzymes. As shown in Table I,
there was no significant difference between the two cell lines
in either glutathione content or glutathione S-transferase
activity. A Northern analysis of the expression of GSTPI-l
RNA is shown in Figure 7. There was no detectable expres-
sion of GSTPI-l RNA in either cell line.
Most, if not all, melphalan-resistant cell lines with altera-
tions in glutathione-dependent pathways demonstrate rever-
sal of resistance with BSO, a glutathione synthesis inhibitor.
The effect of preincubation of WT MCF-7 and MeIR MCF-
7 cells with BSO on melphalan cytotoxicity is shown in
Figure 8. BSO did not specifically reverse the melphalan
resistance of MelR MCF-7 cells, indicating that melphalan
resistance in Mel R MCF-7 cells is not mediated by
glutathione-dependent pathways.
Discussion
We have isolated a melphalan resistant MCF-7 human breast
cancer cell line by serial incubation of MCF-7 cells in in-
creasing concentrations of melphalan. The resulting cell line,
MelR MCF-7, is 30-fold resistant to melphalan. Charac-
terisation of this cell line has revealed that resistance is
associated with a decrease in melphalan accumulation result-
ing from diminished accumulation of drug, and that
glutathione-dependent mechanisms apparently are not res-
ponsible for the acquired resistance seen in MelR MCF-7
cells. It is possible that other unidentified mechanisms of
melphalan resistance co-exist with decreased melphalan trans-
port in MelR MCF-7 cells.
A study by Begleiter et al. (1980) has previously examined
melphalan uptake in WT MCF-7 cells. The time course of
initial melphalan uptake was very similar to the one pre-
sented in this study, with linear uptake for approximately the
first 5 min. The Kt values were similar, 54 lAM (BCH sensi-
tive) vs 70tLM reported here. The Vmax is different in the two
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Figure 6 Efflux of melphalan from WT MCF-7 and MeI1R
MCF-7 cells. Cells were incubated in duplicate or triplicate wells
in 100gM melphalan in PAG transport medium at 37°C for
30 min. The medium was changed to PAG medium without drug
and replicate plates were examined over the time course for
melphalan retention. Values are expressed as a percent of
retained melphalan relative to the intracellular melphalan present
at the end of the loading period. The graph indicates the
mean ± s.d. of two separate determinations performed in tri-
plicate.
Table I Glutathione and glutathione S-transferase in MelR MCF-7
cells
GSH content
nmoles mg-'protein
GST activity
units mg-' protein
WT MCF-7 52 ± 7 7.4± 1.4
MelR MCF-7 43 ± 12 3.7 ± 0.8
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Figure 7 Northern analysis of GSTPI-l (GSTn) RNA expres-
sion in MelR MCF-7 cells. Ten ig of RNA was probed for
expression of GSTPl-l RNA as described in Materials and
methods. RNA from the multidrug resistant MCF-7 subline
AdrR MCF-7, which overexpresses GSTPI-l (Batist, 1986) was
used for a positive control.
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Figure 8 Cytotoxicity assay of melphalan on WT MCF-7 and
MelR MCF-7 cells in the presence and in the absence of BSO.
Cells in triplicate wells were incubated with BSO 100JuM for 24 h
prior to exposure to melphalan. The graph indicates the
mean ± s.d. of five separate determinations performed in tri-
plicate.736 J.A. MOSCOW et al.
reports, 700 amol cell-' min-' vs 2110 amol cell-' min-' in
this study. In both studies, there is evidence that melphalan
uptake is mediated by at least two different transport
systems, one which is BCH-sensitive and which accounts for
most melphalan uptake at low ( 30pM) melphalan concen-
trations, and a BCH-insensitive system. Although the BCH-
insensitive system resembled system ASC in the report by
Begleiter et al. (1980), in that melphalan uptake in their
MCF-7 cell line was both partially sodium-dependent and
inhibited by glutamine excess, in our study we found no
evidence of sodium-dependent melphalan uptake in WT
MCF-7 cells.
Several studies have previously demonstrated an associa-
tion between altered system L transport and melphalan resis-
tance. Redwood and Colvin (1980) reported an in vivo model
of melphalan resistance in a murine L1210 leukaemia cell line
selected for melphalan resistance while grown intraperitoneal
in mice. Strikingly, the L1210 cell lines displayed a response
to BCH inhibition of system L virtually identical to that seen
in MelR MCF-7 cells. These parallel observations are even
more remarkable considering the fact that the Vmax in WT
MCF-7 cells is 10- to 80-fold higher than the Vmax reported
for L1210 cells.
Using an alternative approach, Dantzig et al. (1984)
isolated a Chinese hamster ovary cell line with defective
system L transport by selecting cells with slow growth char-
acteristics after treatment with a mutagen and exposure to
medium containing relatively low concentrations of leucine.
A single isolated clone demonstrated decreased uptake of
system L substrates and relative melphalan resistance under
drug exposure conditions designed to limit non-system L
melphalan uptake.
Two human medulloblastoma cell lines with differences in
relative sensitivity to melphalan have been compared to each
with respect to melphalan transport and glutathione-related
characteristics (Friedman et al., 1988). The comparison of
these cell lines indicated an association between melphalan
resistance and a decreased Vmax for melphalan, although
both system L and system ASC were functional in these cell
lines.
Enhanced melphalan efflux has also been associated with
melphalan resistance. Analysis of a Chinese hamster ovary
cell line selected for colchicine resistance and found to be
cross-resistant to melphalan (Elliot & Ling, 1981) revealed
that decreased melphalan accumulation resulted from en-
hanced melphalan efflux (Begleiter et al., 1983). However,
analysis of melphalan efflux from WT MCF-7 and MelR
MCF-7 cells in the presence of PAG transport medium
(Figure 6) revealed no differences between the WT MCF-7
cells and the resistant subline. Melphalan efflux is a com-
plicated process which can be affected by the concentrations
of extracellular amino acids (Begleiter et al., 1982; Vistica &
Schuette, 1981). However, the sensitive and resistant cell lines
did not differ in the rate of efflux when incubated in amino
acid replete IMEM growth medium after initial melphalan
loading (data not shown).
MelR MCF-7 cells therefore represent the first in vitro
model of transport-associated melphalan resistance in a
human cell line selected for resistance to melphalan. This cell
line also demonstrates that altered system L-mediated trans-
port may be a relevant mechanism of acquired resistance to
melphalan in human tumours. In contrast to system ASC,
system L-mediated transport appears to be responsible for
acquired resistance in every model of melphalan resistance in
which melphalan uptake is impaired. Therefore, augmenta-
tion of system L capacity may be an appropriate strategy for
circumventing melpahalan resistance or increasing melphalan
cytotoxicity.
Glutathione and glutathione-dependent enzymes have fre-
quently been associated with melphalan resistance. Increased
glutathione levels have been observed in a wide variety of cell
lines selected for melphalan resistance (Ahmad et al., 1987a;
Bailey et al., 1992; Bellamy et al., 1991; Green et al., 1984;
Rosenberg et al., 1989; Schecter et al., 1991). Two other
models of melphalan resistance have been reported in which
no increase in glutathione content was found in the resistant
cell lines (Friedman et al., 1988; Gupta et al., 1989). In cell
lines that demonstrate an increase in glutathione levels, BSO
has been found to consistently reverse melphalan resistance
(Ahmad et al., 1987a; Bellamy et al., 1991; Green et al., 1984;
Rosenberg et al., 1989).
The involvement of GSTs in melphalan resistance was
suggested by biochemical studies which demonstrated that
GSTs could conjugate melphalan to 4-(glutathionyl)phenyl-
alanine (Dulick & Fenselau, 1987). The association between
GSTs and models of melphalan resistance has been inconsis-
tent, with an increase in GST activity reported in two cell
lines (Gupta et al., 1989; Schecter et al., 1991) but not in
others (Friedman et al., 1988; Rosenberg et al., 1989). In the
models of melphalan resistance in which GST activity was
elevated, the increase has been associated with an increase in
the pi-class (Gupta et al., 1989; Schecter et al., 1991) and
alpha class (Schecter et al., 1991) GST isozymes. However,
the greatest level of melphalan resistance conferred by trans-
fection of pi and alpha class GST genes was 1.5-fold (Puchal-
ski & Fahl, 1990), while other studies showed no acquisition
of melphalan resistance in GST transfected clones (Leyland-
Jones et al., 1991; Moscow et al., 1989; Nakagawa et al.,
1990). Two other glutathione dependent enzymes have also
been associated with melphalan resistance, gamma glutamyl
transpeptidase (Ahmad et al., 1987b) and gamma glutamyl
cysteine synthetase (Bailey et al., 1992).
Clinical trials combining BSO and melphalan are currently
underway. The use of BSO to decrease glutathione levels and
enhance its antineoplastic cytotoxicity has been successful not
only in vitro, but also in animal models (Friedman et al.,
1989; Kramer et al., 1987). Unfortunately, normal cells may
also employ glutathione-mediated defences, and BSO can add
to melphalan mediated host toxicity (Smith et al., 1989). BSO
may not be effective in clinical trials if it does not increase
the therapeutic index of melphalan, or alternatively, if malig-
nant tumours develop mechanisms of resistance to melphalan
that are not glutathione-dependent. For example, neither of
the in vitro models of melphalan resistance in MCF-7 human
breast cancer cells, the study presented here and a 3-fold
resistant subline reported by Batist et al. (1989), appear to
utilise glutathione-related defences. In contrast to Mel R
MCF-7 cells, the melphalan resistant cell line reported by
Batist et al. does not demonstrate a change in melphalan
uptake; resistance was attributed to an apparent change in
DNA repair capacity.
In summary, MelR MCF-7 cells represent a useful in vitro
model of melphalan resistance mediated by decreased
capacity of the system L amino acid transporter. Melphalan
is administered in a mileau of competitive inhibitors of its
uptake. The potential utility of manipulation of amino acid
transport systems in conjunction with melphalan chemo-
therapy was recently illustrated by a study which demon-
strated increased melphalan uptake in tumour xenografts
after circulating amino acid levels were lowered through
fasting and administration of a protein-free diet (Groothuis
et al., 1992). Such strategies may ultimately improve the
therapeutic effectiveness of melphalan. MelR MCF-7 cells
provide an in vitro model for developing methods of
specifically increasing melphalan uptake by modulating
system L activity.
We wish to thank Drs Edward Minmaugh and Alan Townsend for
their assistance in performing glutathione and GST assays.DECREASED MELPHALAN UPTAKE IN MelR MCF-7 CELLS 737
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